Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy

Sponsor
LiNanlin,Ph.D, Chief Physician,Clinical Professor
Study ID
NCT01652560
Status
Unknown

Conditions

  • Bevacizumab
  • Breast Cancer
  • Molecular Targeted Therapy
  • Neoadjuvant Chemotherapy

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — DRUG
    The patients will be treated with Avastin combined neoadjuvant chemotherapy

Study Details

\- The purpose of this study is to evaluate the efficacy and safety of the application of bevacizumab combined neoadjuvant chemotherapy in HER2-negative breast cancer.

Key Dates

First listed
Jul 30, 2012
Start date
Jun 30, 2012
Status verified
Jul 2012
Primary completion
Jun 30, 2014
Completion
Sep 30, 2014

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: bevacizumab combined neoadjuvant chemotherapy

Primary Outcome Measure

Objective Response Rate [ Time Frame: From enrollment to disease progression ]

Central Contacts

Related Studies